Indices trade moderate cuts; auto shares slide
The headline equity indices traded with substantial losses in the mid-afternoon trade, weighed down by weak forex reserves and global uncertainty. Geopolitical relief and US-India trade optimism offered little support, as caution persisted ahead of the July 9 U.S. tariff deadline.
The Nifty slipped below 25,500 level after hitting days high of 25,669.35 in early trade. Auto shares witnessed profit booking after advancing in the past four consecutive trading sessions.
At 14:25 IST, the barometer index, the S&P BSE Sensex, fell 527.37 points or 0.63% to 83,531.55. The Nifty 50 index fell 148.55 points or 0.58% to 25,489.25.
The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.57% and the S&P BSE Small-Cap index added 0.67%.
The market breadth was positive. On the BSE, 2,206 shares rose and 1,849 shares fell. A total of 181 shares were unchanged.
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, jumped 4.01% to 12.89.
Buzzing Index:
The Nifty Auto index fell 0.73% to 23,831.75. The index rallied 2.33% in the past four trading session.
Maruti Suzuki India (down 2.11%), Hero MotoCorp (down 1.76%), Mahindra & Mahindra (down 0.76%), Bajaj Auto (down 0.68%), TVS Motor Company (down 0.66%), Eicher Motors (down 0.44%), Balkrishna Industries (down 0.36%), Bharat Forge (down 0.10%) and Ashok Leyland (down 0.04%) declined.
On the other hand, Bosch (up 1.43%), Tube Investments of India (up 0.33%) and Tata Motors (up 0.28%) edged higher.
Numbers to Track:
The yield on India's 10-year benchmark federal paper rose 0.14% to 6.319 from the previous close of 6.310.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 85.6150 compared with its close of 85.5050 during the previous trading session.
MCX Gold futures for 5 August 2025 settlement rose 0.45% to Rs 95,924.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.21% to 96.830.
The United States 10-year bond yield lost 0.26% to 4.247.
In the commodities market, Brent crude for August 2025 settlement gained 22 cents or 0.33% to $67.02 a barrel.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Surat, A'bad record steep fall in equity investor registrations
Ahmedabad: With the stock market showing high volatility, Gujarat in May saw a steep fall in new equity investor registrations. Surat registered the biggest decrease — 64% — in April and May compared to the monthly average of the 2025 financial year, while Ahmedabad saw a 62% decrease, a National Stock Exchange (NSE) report shows. Ahmedabad, with 10,000, and Surat (9,400) still ranked among the top 10 districts despite the sharp fall as the state overall registered 56,200 new additions in May to cross the 1 crore unique investors mark. Gunjan Choksi, director of a stock broking firm, said, "Since Jan, there has been a drop in new investors because markets witnessed a bear phase. However, June saw revival in sentiments, we will soon see new investors joining the market in significant numbers." You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad According to the NSE report, within the top 10 districts, Surat saw the steepest drop with a 64% decline in monthly new investor registrations (from ~24,000 in FY25 to ~8,800 in FY26TD), followed closely by 62% in Ahmedabad (from ~24,000 in FY25 to ~9,200 in FY26TD). These two districts significantly influenced the decline in Gujarat's new investor registration momentum. In Maharashtra, Mumbai and Pune recorded 43% and 45% declines respectively in their average monthly run-rates of new investor registrations in FY26TD (as of May 2025) compared to FY25. "In May 2025, investor registrations saw a revival, crossing the 11-lakh mark and breaking a four-month streak of consecutive declines. Uttar Pradesh accounted for the highest share of new additions in May 2025 at 14%, followed by Maharashtra (12%), Tamil Nadu and West Bengal (7% each), and Bihar (6%). Together, these five states contributed 46% of the month's total new registrations. However, the new registration during the month was notably lower than the 17.6 lakh additions recorded in May 2024. During the first two months of FY26, the average monthly investor registrations stood at 10.6 lakh investors — 39% lower than the FY25 monthly average of 17.4 lakh," the report said. It added that all states experienced a decline in their monthly run-rate when comparing the average for FY26TD (as of May 2025) against the full-year average of FY25. "Gujarat recorded the sharpest fall at 63% (from an average of ~1.4 lakh in FY25 to ~52,600 in FY26TD), followed by Rajasthan at 50%. Even the top two states by total investor base saw a notable drop — Maharashtra's monthly average new registrations fell 44% (1.2 lakh in FY26TD vs 2.2 lakh in FY25), while Uttar Pradesh recorded a decline of 39% (1.5 lakh in FY26TD vs 2.5 lakh in FY25)," the report said.
Time of India
2 hours ago
- Time of India
After a robust march, pharma exports slow
New Delhi: India's pharmaceuticals exports grew only 1.5% year-on-year in April and May after an impressive 31.2% jump in March when companies expedited shipments to meet year-end targets and also to avoid potential US tariffs, a top official said. In 2024-25, shipments to the US rose 20.4% to around $10.5 billion from approximately $ 8.7 billion in FY24 despite ongoing challenges related to pricing pressures, regulatory scrutiny, and geopolitical uncertainties, Namit Joshi, chairman of Pharmaceuticals Export Promotion Council ( Pharmexcil ), told ET. The industry remains confident of keeping the momentum and more than double overall pharma exports to $120-130 billion by 2030 from $50-55 billion now, he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Don't Overpay For A Will Or Executor Fees - Do This Instead Consumer Advice Read More Undo Pharmexcil is an authorised exports promotion agency under the commerce and industry ministry. Joshi said the surge in exports in March "was primarily driven by companies expediting shipments to meet financial year-end targets and consolidate annual performance metrics-a recurring trend observed every year." Live Events The announcement of potential tariffs on Indian pharmaceutical products by US President Donald Trump also contributed to the momentum, he said. "Fearing possible future restrictions, several Indian drug manufacturers advanced their shipments to the US, which would have otherwise taken place in April," Joshi said. "This pre-emptive move helped avoid potential tariff impacts but also led to a dip in April exports." Pharma exports in March jumped a staggering 48.8% from February. "While detailed country-wise figures for this period are yet to be released, the US-typically accounting for over 30% of India's total pharma exports-is presumed to have received a significant portion of this March surge," Joshi said. STRATEGIC REPOSITIONING Indian pharma exporters are responding to the dual pressures of regulatory tightening and evolving market demand by strengthening compliance, prioritising complex generics and value-added products, and pursuing strategic investments that enhance their long-term competitiveness in the US, Joshi said. "Heightened regulatory scrutiny, particularly in the form of frequent USFDA inspections and warning letters, has prompted Indian manufacturers to enhance compliance standards and invest in quality upgrades across manufacturing sites," he said. "Companies are increasingly adopting advanced technologies such as automation, data integrity systems, and digitised quality control frameworks to ensure regulatory alignment."
Time of India
2 hours ago
- Time of India
US trade talks at crucial stage; India sticks to agriculture, dairy stand
India and the US are in crucial trade talks. New Delhi is firm on its stance regarding market access in agriculture. This includes GM crops and dairy. India hopes for a deal before July 9. After July 9, reciprocal tariffs from the US will take effect. India will not compromise the interests of its farmers. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The India-US trade pact talks are at a crucial stage with New Delhi sticking to the red line on the issue of market access in agriculture, genetically modified (GM) crops, and dairy, people privy to the development efforts are on to stitch the trade deal before July 9, when 26% reciprocal tariffs by the Donald Trump administration will come into effect, they added. "We are hopeful of a there would be no compromise on the interests of Indian farmers," one the persons told ET."India's stance in these areas is very clear," said another person. "There are red lines that will not be crossed".India's trade negotiators extended their stay in Washington, beyond the scheduled two-day visit ending June 27, as talks with the US government stretched on."The talks are at a critical juncture," said a third person, adding that the deal could also be in multiple phases with certain details following had on April 2 announced a reciprocal tariff of 26% on goods imports from India as part of the administration's trade levies on many countries. The tariffs were paused for 90 days until July 9. However, the baseline tariff of 10% will stay in force even if the reciprocal tariffs are lifted after a trade US wants to be able to sell GM crops and cattle feed to India, a sensitive issue for New Delhi. These segments are difficult and challenging areas for India as local farmers are mostly into sustenance farming and have small land holdings. Washington, on its part, is not willing to lower tariffs below the baseline 10%. "There are certain non-negotiables for India which it has told the US," an official commerce and industry ministry has already informed domestic exporters and industry that talks are on to finalise the first phase and that there would be more phases.
